Form 4: Sage Therapeutics CFO Kimi Iguchi Reports Stock Transactions Following PSU Vesting

CFO of Sage Therapeutics, Kimi Iguchi, reports acquisition and disposal of company stock following the vesting of performance stock units and a purchase under the employee stock purchase plan.

Summary

• Kimi Iguchi, CFO and Treasurer of Sage Therapeutics, reported transactions involving Sage Therapeutics common stock on August 5, 2024.
• These transactions include the acquisition of 13,500 shares of common stock upon the vesting of Performance Stock Units (PSUs) and the disposal of 3,636 shares to cover tax obligations.
• The PSUs vested due to the achievement of certain milestones on August 5, 2024.
• Iguchi also reported beneficial ownership of 1,112 shares purchased on June 28, 2024, under the company's Employee Stock Purchase Plan.
• Following these transactions, Iguchi's total beneficial ownership of Sage Therapeutics common stock is 81,405 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests the achievement of company milestones, but the sale of shares for tax obligations is a neutral event.

Positives

• The vesting of PSUs indicates the achievement of certain company milestones, which can be viewed positively.

Negatives

• The disposal of shares to cover tax obligations could be interpreted as a slight negative, although it's a common practice.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's confidence in the company's future performance.

Comparison to Industry Standards

• Stock transactions by executives are a normal part of compensation packages in publicly traded companies like Sage Therapeutics.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies such as Biogen, Vertex Pharmaceuticals, and Amgen.

Stakeholder Impact

• The vesting of PSUs and subsequent stock transactions may have a minor impact on shareholders, potentially influencing stock price.

Key Dates